Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSE-010 on Appetite and Food Intake in Overweight and Obese Subjects
NCT06621017Phase 2Completed
- Sponsor
- Rose Pharma
- Start
- Sep 2024
- Primary completion
- Feb 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LY307161 in obesity (3 arms), sponsored by Rose Pharma. Primary endpoint: Food Consumption at 30 minutes. Started Sep 2024; status: completed.
02
Drugs
LY307161
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06621017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06621017.